Grail's cancer blood test faces high-stakes FDA review
A blood test designed to spot signs of multiple cancers in apparently healthy people faces its first major regulatory hurdle Wednesday as advisers to the U.S. government review how well it works.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
USP15 enzyme emerges as potential target for ovarian cancer treatment
-
Uterus transplantation shows improving outcomes and successful births nationwide
-
The heart effects of antidepressants may depend as much on the patient as the drug
-
AI model predicts immunotherapy-related pneumonitis risk from CT scans
-
Investigating brain stimulation as an alternative to medication in the treatment of epilepsy
-
Study identifies shared pathway driving cardiac fibrosis
-
Overprescribing can take a toll on older people's health and independence—here's what can be done
-
Beetroot juice may make swimming feel easier without making swimmers faster